Less than a tenth of people that would benefit from weight-loss injections like Wegovy can access them, states the WHO as it issues its first advice on the medications.
With in excess of 1,000,000,000 people worldwide now living with obesity, it is advocating for increased and just access to GLP-1 medication.
Based on estimates, over two billion are projected to be obese by 2030 if no action is taken.
"The latest guidance recognises that obesity is a lifelong illness that can be managed with thorough and continuous support," remarked WHO director-general Tedros Adhanom Ghebreyesus.
Significant expense, constrained manufacturing, and supply-chain constraints are major obstacles to universal availability to the injections that can help people shift substantial weight, notes the agency.
Skinny Jab Shortage
Despite the present best projected case, the production of GLP-1 therapies could only cover around 100 million people – under 10% of eligible patients, as stated by the WHO.
The recommendation encourages governments and firms to expand access, through approaches including patent sharing.
A patent on the active ingredient – the main component of Novo Nordisk's Wegovy – is scheduled to end in multiple nations in 2026.
The Way Obesity Drugs Operate
The injections mimick a biological compound to reduce digestion speed, curb appetite and boost satiety so individuals reduce food intake.
Individuals usually start to lose weight after several weeks of beginning the weekly injections.
Research points to patients may regain a significant portion within a year of discontinuing the treatment, when their typical food cravings return.
To be carrying excess weight increases your chance for developing health problems, including type 2 diabetes, cardiovascular issues, stroke, and certain malignancies.
Obesity concerns individuals in all nations and was responsible for 3.7 million fatalities worldwide in 2024, as per the health agency.
